12 Month Price Forecast For OABI
Distance to OABI Price Forecasts
OABI Price Momentum
🤔 Considering OmniAb (OABI)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 8:23 PM UTC
OABI Analyst Ratings & Price Targets
Based on our analysis of 9 Wall Street analysts, OABI has a consensus that is bullish. The median price target is $10.00, with forecasts ranging from $7.00 to $12.00. Currently, there are 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With OABI currently trading at $3.22, the median price forecast suggests a 210.6% upside. The most optimistic forecast comes from Stephen Willey at Stifel, projecting a 272.7% upside, while Conor McNamara at RBC Capital provides the most conservative target, suggesting a 117.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OABI Analyst Consensus
OABI Price Target Range
Latest OABI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OABI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $11.00 |
| Nov 14, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Aug 19, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $7.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $11.00 |
| May 14, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Mar 26, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $10.00 |
| Mar 22, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Mar 21, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $7.00 |
| Mar 21, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $11.00 |
| Nov 14, 2023 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $11.00 |
| May 12, 2023 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Apr 21, 2023 | Benchmark | Robert Wasserman | Buy | Initiates | $8.00 |
| Apr 13, 2023 | Craig-Hallum | Matt Hewitt | Buy | Initiates | $10.00 |
| Mar 31, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $11.00 |
| Feb 22, 2023 | Cowen & Co. | Steven Mah | Outperform | Initiates | $10.00 |
| Feb 13, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $11.00 |
| Dec 20, 2022 | Truist Securities | Robyn Karnauskas | Buy | Initiates | $10.00 |
| Dec 16, 2022 | Credit Suisse | Tiago Fauth | Outperform | Initiates | $13.00 |
Stocks Similar to OmniAb, Inc.
The following stocks are similar to OmniAb based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
OmniAb, Inc. (OABI) Financial Data
OmniAb, Inc. has a market capitalization of $388.45M with a P/E ratio of -6.3x. The company generates $20.41M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -23.8% quarter-over-quarter, while maintaining an operating margin of -473.7% and return on equity of -20.5%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
OmniAb, Inc. (OABI) Company Overview
About OmniAb, Inc.
Biotechnology company specializing in antibody discovery.
OmniAb, Inc. utilizes its proprietary technology platform to discover and provide therapeutic antibody solutions. The company partners with drug developers to create and screen diverse antibody repertoires, generating optimal antibodies that facilitate the development of human therapeutic candidates. Revenue is primarily generated through collaborations and partnerships with pharmaceutical companies seeking to leverage its advanced antibody discovery technologies.
Founded in 2012 and headquartered in Emeryville, California, OmniAb employs genetically modified transgenic animals such as OmniRat, OmniChicken, and OmniMouse to produce antibodies with human sequences. The company's innovative products, including OmniFlic and OmniClic for bispecific applications, and OmniTaur for unique structural characteristics, position it as a leader in the biotechnology field. Additionally, OmniDeep employs AI and machine learning tools to enhance therapeutic discovery and optimization.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
106
CEO
Mr. Matthew W. Foehr
Country
United States
IPO Year
2022
Website
www.omniab.comOmniAb, Inc. (OABI) Latest News & Analysis
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
1 month agoOmniAb, Inc. (NASDAQ: OABI) presented its technologies at the 2024 Antibody Engineering & Therapeutics Conference in San Diego, highlighting advancements in multispecific antibody development.
OmniAb's presentation at a key industry conference highlights its innovative technologies, potentially enhancing its market position and attracting investor interest in future growth.
OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript
2 months agoOmniAb, Inc. (NASDAQ: OABI) will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring key executives and analysts from leading firms.
The Q3 2024 earnings call will provide insights into OmniAb's financial performance and strategic direction, influencing investor sentiment and stock price movements.
OmniAb, Inc. (NASDAQ: OABI) reported Q3 2024 financial results, showing growth in key metrics and progress in technology and partnerships.
OmniAb's strong quarterly results and expanding partnerships signal robust growth and innovation, which could enhance investor confidence and drive stock performance.
OmniAb, Inc. reported a quarterly loss of $0.16 per share, missing the Zacks Consensus Estimate of a $0.14 loss, and matching its loss from the same quarter last year.
OmniAb's larger-than-expected quarterly loss signals operational challenges, potentially affecting investor confidence and stock performance.
OmniAb, Inc. (NASDAQ: OABI) will participate in two investor conferences in November: Stifel Healthcare Conference (Nov 18-19) and Jefferies London Healthcare Conference (Nov 19-21).
Participation in investor conferences can enhance visibility and credibility, potentially attracting new investors and influencing stock performance in the short term.
OmniAb, Inc. (NASDAQ: OABI) will release Q3 financial results on November 12, 2024, after market close, followed by a conference call at 4:30 p.m. ET.
OmniAb's upcoming financial report and conference call could reveal key insights into its performance, affecting stock valuation and investor sentiment.
Frequently Asked Questions About OABI Stock
What is OmniAb, Inc.'s (OABI) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, OmniAb, Inc. (OABI) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $7.00.
Is OABI stock a good investment in 2025?
According to current analyst ratings, OABI has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for OABI stock?
Wall Street analysts predict OABI stock could reach $10.00 in the next 12 months. This represents a 210.6% increase from the current price of $3.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is OmniAb, Inc.'s business model?
OmniAb, Inc. utilizes its proprietary technology platform to discover and provide therapeutic antibody solutions. The company partners with drug developers to create and screen diverse antibody repertoires, generating optimal antibodies that facilitate the development of human therapeutic candidates. Revenue is primarily generated through collaborations and partnerships with pharmaceutical companies seeking to leverage its advanced antibody discovery technologies.
What is the highest forecasted price for OABI OmniAb, Inc.?
The highest price target for OABI is $12.00 from Stephen Willey at Stifel, which represents a 272.7% increase from the current price of $3.22.
What is the lowest forecasted price for OABI OmniAb, Inc.?
The lowest price target for OABI is $7.00 from Conor McNamara at RBC Capital, which represents a 117.4% increase from the current price of $3.22.
What is the overall OABI consensus from analysts for OmniAb, Inc.?
The overall analyst consensus for OABI is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are OABI stock price projections?
Stock price projections, including those for OmniAb, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
